~~UNITED~~ ~~STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549~~__________________________________________________________________________________

~~Form~~UNITED ~~6-K~~STATES

~~REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE~~ SECURITIES AND EXCHANGE ~~ACT OF 1934~~COMMISSION

~~For~~WASHINGTON, ~~the~~D.C. ~~month of November 2025~~20549

__________________________________________________________________________________

FORM 6-K

__________________________________________________________________________________

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

December 1st, 2025

Commission File Number: 001-39777

~~Nanobiotix S.A.(Translation of registrant's name into English)~~__________________________________________________________________________________

60NANOBIOTIX ~~Rue de Wattignies 75012 Paris, France(Address of principal executive office)~~S.A.

~~Indicate~~(Translation byof ~~check mark whether the~~ registrant’s ~~files~~name orinto ~~will file annual reports under cover of Form 20-F or Form 40-F.Form 20-F [ X ] Form 40-F [ ]~~English)

On November 24, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. (c) Exhibit 99.1. Press release dated November 24, 2025___________________________________________________________________________

60 rue de Wattignies 75012 Paris, France

(Address of principal executive offices)

__________________________________________________________________________________

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On December 1, 2025, Nanobiotix SA (the “Registrant”) provided notification and public disclosure of transactions by persons discharging managerial responsibilities (“PDMR”) and persons closely associated with them in accordance with the requirements of the EU Market Abuse Regulation (“MAR”), which are attached hereto as Exhibit 99.1.

EXHIBIT INDEX


Exhibit			Description
99.1			PDMR notifications pursuant to MAR, dated December 1, 2025 (French version)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Nanobiotix S.A.
		(Registrant)
Date: November 24, 2025		/s/ Bart Van Rhijn
		Bart Van Rhijn
		Chief Financial Officer

NANOBIOTIX S.A.

Date: December 1, 2025 By: Laurent Levy, Chairman of the Executive Board

Filing Compare · Nanobiotix S.A.